Prelude Therapeutics Incorporated
NASDAQ:PRLDBiotechnology
-$0.14 today
- Market cap
- $191.00M
- Beta
- 1.01
- P/E (TTM)
- -4.5
- EPS (TTM)
- -$0.94
Volume 0.23M
Average 0.38M
PRLD Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Prelude Therapeutics IncorporatedNASDAQ: PRLD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $391K fell 10.1% year over year, behind the -6.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 6.5% from the prior quarter. Over 3 fiscal years it compounded at +8.9% a year.
Context
- Depreciation & amortization amounted to 14.1% of revenue in FY2025, down 11.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -10.1% toward the trailing-twelve-month pace of -6.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.71M USD
- Year-over-year change
- -3.4%
- 4-year CAGR
- +16.9%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.71M | -3.4% |
| FY2024 | 2024-12-31 | 1.77M | +51.6% |
| FY2023 | 2023-12-31 | 1.17M | -11.7% |
| FY2022 | 2022-12-31 | 1.32M | +44.7% |
| FY2021 | 2021-12-31 | 915K | — |
Depreciation & Amortization vs competitors
How PRLD compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -6.4% is the 6th highest of 11, against a peer median of -2.5%.
- Depreciation & amortization amounts to 10.0% of revenue for PRLD, versus a peer median of 29.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $7.54M USD | -16.0% | -1.1% | 3350.2% | |
| LTM Mar 2026 | $4.93M USD | +55.9% | +19.6% | 7.1% | |
| LTM Mar 2026 | $4.42M USD | +82.7% | +85.3% | 31.9% | |
| LTM Mar 2026 | $3.13M USD | -28.6% | +0.0% | 27.9% | |
| FY2025 | €2.8M EUR | -46.2% | +47.6% | 62.4% | |
| LTM Mar 2026 | $2.79M USD | -10.3% | +0.1% | 9.9% | |
| LTM Mar 2026 | $1.67M USD | -6.4% | +8.9% | 10.0% | |
| LTM Mar 2026 | $786.79K USD | +70.5% | +36.1% | — | |
| LTM Mar 2026 | $334K USD | +5.4% | +13.8% | 1.0% | |
EPRXEupraxia Pharmaceuticals Inc. | LTM Mar 2026 | $262.3K USD | +45.1% | +30.9% | — |
| LTM Mar 2026 | $226K USD | -16.3% | +27.5% | 383.1% | |
| Peer median (excluding PRLD) | — | -2.5% | +23.6% | 29.9% | |
Competitors are the stored peer set for PRLD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 7M | 12.14M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 1.71M |
| Gross Profit | 0 | 0 | 0 | 7M | 10.43M |
| Gross Margin | — | — | — | 100.0% | 85.9% |
| Research & Development | 86.78M | 92.89M | 103.39M | 118M | 94.3M |
| Selling, General & Admin | 26.96M | 30.65M | 28.88M | 28.72M | 22.41M |
| Operating Expenses | 113.74M | 123.54M | 132.28M | 146.71M | 115M |
| Depreciation & Amortization | 915K | 1.32M | 1.17M | 1.77M | 1.71M |
| EBITDA | (110.78M) | (114.11M) | (120.66M) | (125.4M) | (97.79M) |
| EBITDA Margin | — | — | — | -1791.4% | -805.5% |
| Operating Income | (113.74M) | (123.54M) | (132.28M) | (139.71M) | (104.57M) |
| Operating Margin | — | — | — | -1995.9% | -861.3% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 2.04M | 8.1M | 10.44M | 12.54M | 5.07M |
| Income Before Tax | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Pre-Tax Margin | — | — | — | -1816.8% | -819.6% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (111.69M) | (115.44M) | (121.83M) | (127.17M) | (99.5M) |
| Net Margin | — | — | — | -1816.8% | -819.6% |
| EPS (Basic) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| EPS (Diluted) | (2.33) | (2.27) | (2.02) | (1.68) | (1.29) |
| Weighted Avg Shares | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
| Weighted Avg Shares (Diluted) | 47.6M | 47.37M | 60.36M | 75.81M | 76.96M |
Prelude Therapeutics Incorporated
NASDAQ:PRLD
Intrinsic Alpha fair value
Locked
Current Price
$3.30
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.